Menu
No results found.
4530
Hisamitsu Pharmaceutical Co., Inc. – TYO
Weekly Share Price & Valuation Overview
Market Overview
Open
4085.0000
Close
4167.0000
High
4172.0000
Low
4070.0000
Trend
0.26239
Hisamitsu Pharmaceutical Co., Inc.
Japan
• TYO - Tokyo Stock Exchange
• 4530
• Currency: JPY
Hisamitsu Pharmaceutical Co., Inc. manufactures and sells pharmaceuticals in Japan. The company provides external pain-relieving drugs under the SALONPAS, NOBINOBI, SALONSIP, AIR, SALONPAS, and FEITAS; BUTENALOCK, a remedy for athlete's foot; and ALLEGRA FX, a sinus medication for allergies. It also manufactures and sells quasi-drugs and cosmetics; MOHRUS TAPE and MOHRUS PAP XR, a transdermal analgesic anti-inflammatory drug; and patches for female hormone, asthma, and overactive bladders. The company exports its products to Asia, the United States of America, and the European area. Hisamitsu Pharmaceutical Co., Inc. was founded in 1847 and is headquartered in Tosu, Japan.
Key strengths
- High gross margin (≥35%) suggests strong pricing power or cost control.
- Revenue growth ≥10% indicates solid top-line momentum.
- Earnings growth ≥10% supports improving profitability trajectory.
- Quick ratio ≥1.0 indicates obligations can be met without inventory.
- Net cash balance sheet provides flexibility for downturns and investment.
Scale & Structure
Core size and share structure. TTM values unless noted. “Estimated” where reconciled from per-share × shares.
- Market Cap Total equity value of the company (share price × shares outstanding).
- JPY 303.83B
- Enterprise Value Operating value: market cap + total debt − cash.
- JPY 198.31B
- Total Revenue (TTM) Sales over the last twelve months. May be estimated from revenue per share when inconsistent.
- JPY 154.86B
- Gross Profit (TTM) Revenue minus cost of goods sold over the last twelve months. Hidden for financial institutions or if redundant.
- JPY 91.68B
- EBITDA (TTM) Earnings before interest, taxes, depreciation and amortization (TTM). Hidden for financials or if implausible.
- JPY 24.74B
- Revenue per Share (TTM) Total revenue divided by shares outstanding (may be estimated).
- JPY 2.12K
- EPS (TTM) Earnings per share over the last twelve months (may be estimated from net income ÷ shares).
- 266.44
- Dividend Yield Annual dividend ÷ share price. Reconciled using dividend per share when available.
- 2.11%
- Shares Outstanding
- 71.27M
- Implied Shares Outstanding
- 73.04M
Profitability & Efficiency
TTM basis. “Reconciled” = numerator ÷ TTM revenue. Margins reflect latest TTM calculations.
- Operating Margin (TTM) Operating income ÷ revenue over the last twelve months (reconciled when possible).
-
9.71%
- EBITDA Margin (TTM) Reconciled EBITDA ÷ revenue over the last twelve months (suppressed if EBITDA implausible/financials).
-
15.97%
- Gross Margin (TTM) Reconciled Strong Gross profit ÷ revenue over the last twelve months (reconciled when possible).
-
59.20%
Growth
Growth rates are YoY unless labeled QoQ.
- Revenue Growth Strong Year-over-year revenue growth.
-
20.00%
- Earnings Growth (YoY) Strong Year-over-year earnings growth.
-
27.73%
Liquidity & Solvency
Balance-sheet health. Debt metrics shown as latest ratios; D/E is a ratio (not %).
- Quick Ratio Adequate Liquid current assets ÷ current liabilities (ex-inventory).
- 3.59
- Debt to Equity Total debt ÷ shareholder equity; leverage.
- 0.97
- Total Cash Cash and equivalents.
- JPY 118.13B
- Total Debt Short + long-term interest-bearing debt.
- JPY 2.65B
- Net Debt Net Cash Total debt − cash (negative = net cash).
- JPY -115.48B
- Debt / EBITDA Leverage relative to operating earnings; lower is safer.
- 0.11
Sharemaestro House View
Confidence: 1
Sharemaestro internal conviction (0–3, higher is better).
Risk: 1
Sharemaestro internal risk profile (0–3, higher is safer).
Operational: 3
Operational quality/consistency (0–3, higher is better).
Composite Score: 2
Overall internal composite (0–3, higher is better).
Suggested Allocation: 3.33%
Indicative portfolio weighting suggestion based on house view.
Structural Insights
(experimental)
Ownership & Liquidity
Free Float
Proportion of shares available for public trading.
—
Insiders
Shares held by company insiders (officers, directors).
23.7%
Institutions
Shares held by institutions (funds, pensions).
34.8%
Capital Structure
Potential Dilution
Increase in share count if options/convertibles exercise.
2.5%
Net Debt
Total debt − cash (negative = net cash).
JPY -115.48B
-74.6% of revenue
Net debt relative to revenue — debt load vs business scale.
Resilience Score
0–100 composite of liquidity, leverage and cash conversion; higher is better. If inputs are unavailable, we estimate using proxies (Net debt vs revenue, Cash-to-Debt). It is a guide, not a rating.
100
Methodology Notes
- Margins shown on a TTM basis. “Reconciled” = numerator ÷ TTM revenue for internal consistency.
As of: 2025-08-18 10:04
Disclaimer: Information is compiled from publicly available sources and is subject to errors and omissions. It is provided as a guide only and does not constitute investment advice. Please do your own research.
AI generated insights not available yet. Sign in to generate the snapshot.